Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL182987 | 0.96 | — | — | |
| Alcohol SCHEMBL15224974 | 0.96 | ALDH1A1 (0.50) | ALDH1A1TSHR | |
| Alcohol SCHEMBL1847595 | 0.86 | MEN1 (0.44) | ALDH1A1TSHR | |
| Alcohol SCHEMBL11224298 | 0.86 | MEN1 (0.44) | ALDH1A1TSHR | |
| Alcohol SCHEMBL11224304 | 0.86 | MEN1 (0.44) | ALDH1A1TSHR | |
| Methyl Alcohol SCHEMBL2405349 | 0.84 | — | — | |
| Water SCHEMBL127130 | 0.83 | — | — | |
| Water SCHEMBL29088662 | 0.83 | TSHR (0.32) | ALDH1A1TSHR | |
| Water SCHEMBL337744 | 0.83 | TSHR (0.32) | ALDH1A1TSHR | |
| 2-Methoxyethanol SCHEMBL997154 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-20230027295-A1 | FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20220009933-A1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-13 | — | — | US | disclosed |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | Beta Therapeutics Pty Ltd (AU) | 2021-05-06 | — | — | US | disclosed |
| WO-2021057818-A1 | FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| EP-3666758-A1 | PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE | AbbVie Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| EP-3555051-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | disclosed |
| EP-3554505-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018107200-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty Ltd (AU) | 2018-06-21 | — | — | WO | disclosed |
| WO-2007103554-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103260-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070142382-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| WO-2007058580-A1 | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058583-A2 | NOVEL 2-AMINO-HETEROCYCLES USEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058602-A2 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, NEURODEGENERATION AND DEMENTIA. | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| US-20060161003-A1 | Process for producing oxycarbonyl-substituted piperazine derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1548010-A1 | PROCESS FOR PRODUCING OXYCARBONYL-SUBSTITUTED PIPERAZINE DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027295-A1 | FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | F11, TFPI, F7 | ALDH1A1 3516/4885TSHR 2682/4885 |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | ALDH1A1 2240/4885TSHR 1466/4885 |
| US-20070142382-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | ALDH1A1 404/4885TSHR 2851/4885 |
| US-20220009933-A1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | IRAK4, IRAK1, IRAK2 | ALDH1A1 3048/4885TSHR 3132/4885 |
| US-20060161003-A1 | Process for producing oxycarbonyl-substituted piperazine derivative | DHPS, AQP4, OGFOD1 | ALDH1A1 1595/4885TSHR 4687/4885 |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | HPSE, HEXD, ENGASE | ALDH1A1 2194/4885TSHR 3759/4885 |
| US-11718609-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | ALDH1A1 2194/4885TSHR 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.